Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 6Myeloproliferative Disorders 5Glioma 5Cholangiocarcinoma 5Leukemia 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Ependymoma 2Chondrosarcoma 2Biliary Tract Neoplasms 2Xanthogranuloma, Juvenile 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Unknown Primary 1Neoplasm, Residual 1Lymphoma, Follicular 1IDH1-Mutated Malignancies 1

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 3Pancreaticoduodenectomy 2Oxaliplatin 2Irinotecan 2titanium silicide 1tislelizumab 1sonidegib 1paricalcitol 1mitazalimab 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1glucoraphanin 1devimistat 1Transurethral Resection of Prostate 1Tissue Banks 1Taxes 1Specimen Handling 1Saline Solution 1S 1 (combination) 1Ropivacaine 1Robotic Surgical Procedures 1Positron Emission Tomography Computed Tomography 1Parturition 1PEGPH20 1Neoadjuvant Therapy 1Losartan 1Leucovorin 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Ductal Adenocarcinoma × ivosidenib × Clear all
NCT05209074 2025-09-05

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Case Comprehensive Cancer Center

Phase 1 Active not recruiting
16 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡